Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 43.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,263,353 shares of the company’s stock after buying an additional 382,608 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Amylyx Pharmaceuticals were worth $4,775,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Walleye Capital LLC lifted its stake in shares of Amylyx Pharmaceuticals by 986.5% in the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after purchasing an additional 608,874 shares during the last quarter. Alpha Wave Global LP acquired a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at $2,169,000. Geode Capital Management LLC lifted its stake in shares of Amylyx Pharmaceuticals by 17.5% in the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock valued at $1,786,000 after purchasing an additional 82,173 shares during the last quarter. FMR LLC lifted its stake in shares of Amylyx Pharmaceuticals by 292.0% in the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after purchasing an additional 164,622 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after purchasing an additional 83,048 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the sale, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. This represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.47, for a total value of $41,122.97. Following the sale, the chief executive officer now owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. This trade represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,169 shares of company stock worth $97,274 in the last quarter. 11.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Robert W. Baird raised Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.33.

Amylyx Pharmaceuticals Trading Down 1.1 %

AMLX opened at $3.63 on Monday. The stock’s 50-day moving average price is $3.51 and its 200 day moving average price is $3.94. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $7.27. The firm has a market cap of $321.63 million, a price-to-earnings ratio of -0.95 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter. On average, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.